Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor [EPC]

22332 reported adverse events

Drugs of this class: VALGANCICLOVIR GANCICLOVIR

These side effects are most commonly reported by patients taking drugs of the Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor [EPC] class:

# Side effect Count
0 OFF LABEL USE 3421
1 DRUG INEFFECTIVE 2427
2 CYTOMEGALOVIRUS INFECTION 2219
3 NEUTROPENIA 1333
4 PYREXIA 1187
5 DIARRHOEA 1014
6 LEUKOPENIA 976
7 PANCYTOPENIA 960
8 PRODUCT USE IN UNAPPROVED INDICATION 954
9 DRUG RESISTANCE 927
See all common reactions for Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor [EPC]

Drugs of the Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 CYTOMEGALOVIRUS SYNDROME 84 0.5091
1 ENCEPHALITIS CYTOMEGALOVIRUS 203 0.4635
2 CYTOMEGALOVIRUS GASTROINTESTINAL INFECTION 102 0.3423
3 SMOOTH MUSCLE CELL NEOPLASM 136 0.3254
4 CYTOMEGALOVIRUS OESOPHAGITIS 85 0.2310
5 CYTOMEGALOVIRUS VIRAEMIA 924 0.2075
6 CYTOMEGALOVIRUS ENTERITIS 71 0.1994
7 DELAYED GRAFT FUNCTION 134 0.1885
8 CYTOMEGALOVIRUS CHORIORETINITIS 322 0.1650
9 CYTOMEGALOVIRUS INFECTION REACTIVATION 676 0.1529
See all enriched reactions for Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor [EPC]